Ocular Therapeutix Inc. (OCUL)

4.45
NASDAQ : Health Technology
Prev Close 4.44
Day Low/High 4.35 / 4.49
52 Wk Low/High 2.35 / 7.31
Avg Volume 773.50K
Exchange NASDAQ
Shares Outstanding 47.20M
Market Cap 209.55M
EPS -1.60
P/E Ratio N/A
Div & Yield N.A. (N.A)
OCUL Crosses Below Key Moving Average Level

OCUL Crosses Below Key Moving Average Level

In trading on Monday, shares of Ocular Therapeutix Inc crossed below their 200 day moving average of $5.91, changing hands as low as $5.88 per share. Ocular Therapeutix Inc shares are currently trading off about 2.1% on the day.

Ocular Therapeutix™ Announces FDA Acceptance Of NDA Resubmission For DEXTENZA®

Ocular Therapeutix™ Announces FDA Acceptance Of NDA Resubmission For DEXTENZA®

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has received acknowledgement from...

Ocular Therapeutix Is Now Oversold (OCUL)

Ocular Therapeutix Is Now Oversold (OCUL)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Ocular Therapeutix™ Announces NDA Resubmission Of DEXTENZA™

Ocular Therapeutix™ Announces NDA Resubmission Of DEXTENZA™

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, has announced the resubmission of the Company's New Drug...

Ocular Therapeutix™ To Present At The 2018 JMP Securities Life Sciences Conference

Ocular Therapeutix™ To Present At The 2018 JMP Securities Life Sciences Conference

Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Antony Mattessich, President and Chief...

Ocular Therapeutix™ Reports First Quarter 2018 Financial Results And Business Update

Ocular Therapeutix™ Reports First Quarter 2018 Financial Results And Business Update

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced financial results for the first quarter...

Ocular Therapeutix™ Announces Treatment Of First Patient In Phase 1 Clinical Trial Of OTX-TIC (travoprost Intracameral Implant) For The Treatment Of Glaucoma And Ocular Hypertension

Ocular Therapeutix™ Announces Treatment Of First Patient In Phase 1 Clinical Trial Of OTX-TIC (travoprost Intracameral Implant) For The Treatment Of Glaucoma And Ocular Hypertension

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the treatment of the first patient in a...

Ocular Therapeutix™ To Present Data At The Association For Research In Vision And Ophthalmology (ARVO) Annual Meeting

Ocular Therapeutix™ To Present Data At The Association For Research In Vision And Ophthalmology (ARVO) Annual Meeting

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that data from its preclinical research will...

Ocular Therapeutix™ To Report First Quarter 2018 Financial Results

Ocular Therapeutix™ To Report First Quarter 2018 Financial Results

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report first quarter...

Markets Recovering From Latest Trump Tweetstorm

Markets Recovering From Latest Trump Tweetstorm

Wall Street discounting talk of bombing Syria from president.

Biotechs Take the Lead This Morning

Biotechs Take the Lead This Morning

Whether this market continues to bounce is going to depend a great degree on the FAANG names.

Ocular Therapeutix™ To Present At The H.C. Wainwright Annual Global Life Sciences Conference In Monte Carlo, Monaco On April 8-10, 2018

Ocular Therapeutix™ To Present At The H.C. Wainwright Annual Global Life Sciences Conference In Monte Carlo, Monaco On April 8-10, 2018

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced it...

Dip Buyers Are Losing Their Confidence -- And They Have No Interest in Facebook

Dip Buyers Are Losing Their Confidence -- And They Have No Interest in Facebook

The longer the stock market goes without a better bounce, the bigger the risk.

You Trading Small-Cap Stocks? You Should Be

You Trading Small-Cap Stocks? You Should Be

Right now this is a market for stock pickers and not timers.

OCUL: Insiders vs. Shorts

OCUL: Insiders vs. Shorts

The most recent short interest data was recently released for the 02/15/2018 settlement date, and Ocular Therapeutix Inc is one of the most shorted stocks of the Russell 3000, based on 9.73 "days to cover" versus the median component at 3.69. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Ocular Therapeutix™ Reports Fourth Quarter And Year End 2017 Financial Results And Business Update

Ocular Therapeutix™ Reports Fourth Quarter And Year End 2017 Financial Results And Business Update

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced...

Ocular Therapeutix™ To Present At The Cowen And Company 38th Annual Health Care Conference

Ocular Therapeutix™ To Present At The Cowen And Company 38th Annual Health Care Conference

Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Michael...

Ocular Therapeutix™ To Report Fourth Quarter 2017 Financial Results

Ocular Therapeutix™ To Report Fourth Quarter 2017 Financial Results

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye, today announced...

Ocular Therapeutix™ To Participate In The 2018 Glaucoma 360 Meeting In San Francisco

Ocular Therapeutix™ To Participate In The 2018 Glaucoma 360 Meeting In San Francisco

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye, today announced...

Ocular TherapeutixTM Announces Closing Of Public Offering Of Common Stock

Ocular TherapeutixTM Announces Closing Of Public Offering Of Common Stock

Ocular Therapeutix™, Inc. (NASDAQ: OCUL) today announced the closing of its underwritten public offering of 7,475,000 shares of its common stock at a public offering price of $5.

Interesting OCUL Put And Call Options For September 21st

Interesting OCUL Put And Call Options For September 21st

Investors in Ocular Therapeutix Inc saw new options begin trading this week, for the September 21st expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 238 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Ocular TherapeutixTM Announces Pricing Of Public Offering Of Common Stock

Ocular TherapeutixTM Announces Pricing Of Public Offering Of Common Stock

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), today announced the pricing of an underwritten public offering of 6,500,000 shares of its common stock at a public offering price of $5.

Ocular Therapeutix™ Announces Proposed Public Offering Of Common Stock

Ocular Therapeutix™ Announces Proposed Public Offering Of Common Stock

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), today announced that it has commenced an underwritten public offering of its common stock pursuant to a shelf registration statement that was previously filed with and...

First Week of February 16th Options Trading For Ocular Therapeutix (OCUL)

First Week of February 16th Options Trading For Ocular Therapeutix (OCUL)

Investors in Ocular Therapeutix Inc saw new options begin trading this week, for the February 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the OCUL options chain for the new February 16th contracts and identified the following put contract of particular interest.

Ocular Therapeutix™ Announces Kevin Hanley As Senior Vice President, Technical Operations And Naymisha Patel As Vice President Of Quality

Ocular Therapeutix™ Announces Kevin Hanley As Senior Vice President, Technical Operations And Naymisha Patel As Vice President Of Quality

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye, today announced the...

Ocular Therapeutix™ Provides Legal Update

Ocular Therapeutix™ Provides Legal Update

Ocular Therapeutix™, Inc. (NASDAQ: OCUL) (the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye,...

Ocular Therapeutix™ To Participate In The Guggenheim Securities 5th Annual Boston Healthcare Conference

Ocular Therapeutix™ To Participate In The Guggenheim Securities 5th Annual Boston Healthcare Conference

Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye, today announced that...

Oversold Conditions For Ocular Therapeutix (OCUL)

Oversold Conditions For Ocular Therapeutix (OCUL)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Ocular Therapeutix™ Reports Third Quarter 2017 Financial Results And Provides Corporate Update

Ocular Therapeutix™ Reports Third Quarter 2017 Financial Results And Provides Corporate Update

Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye, today announced...

Ocular Therapeutix™ To Report Third Quarter 2017 Financial Results

Ocular Therapeutix™ To Report Third Quarter 2017 Financial Results

Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye, today announced that...

TheStreet Quant Rating: D- (Sell)